Last updated on February 2018

Immune Disorder HSCT Protocol


Brief description of study

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

Clinical Study Identifier: NCT01821781

Contact Investigators or Research Sites near you

Start Over

Jeffrey Bednarski, MD

Washington University
Saint Louis, MO United States
  Connect »

Troy Quigg, DO, MS

Methodist Heathcare
San Antonio, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.